Personalized extended interval dosing of natalizumab in MS
Zoé L. E. van Kempen(Amsterdam Neuroscience), Joep Killestein(Amsterdam UMC Location Vrije Universiteit Amsterdam), Birgit I. Lissenberg‐Witte(OLVG), Theo Rispens(Sanquin), Mike P. Wattjes(Humboldt-Universität zu Berlin), Bob W. van Oosten(Amsterdam Neuroscience), Annick de Vries(Sanquin), Frederik Barkhof(Netherlands Institute for Neuroscience), Nynke F. Kalkers(OLVG), Charlotte E. Teunissen(Amsterdam Neuroscience), Anja ten Brinke(Sanquin), Jop Mostert(Rijnstate Hospital), E.L.J. Hoogervorst(St. Antonius Ziekenhuis), Bernard M.J. Uitdehaag(Amsterdam UMC Location Vrije Universiteit Amsterdam)
Cited by 56
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k
IgG Subclasses and Allotypes: From Structure to Effector Functions
|Frontiers in Immunology|2014|2.6k